TVTX Q2 2023 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M-40.6% YoY

Gross Profit

$31M95.5% margin

Operating Income

-$104M-322.9% margin

Net Income

-$86M-266.0% margin

EPS (Diluted)

$-1.13

QoQ Revenue Growth

-43.5%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$73M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$736M

Total Liabilities

$620M

Stockholders' Equity

$116M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$54M	-40.6%
Gross Profit	$31M	$52M	-41.0%
Operating Income	-$104M	-$65M	-58.8%
Net Income	-$86M	-$67M	-27.7%

Revenue Segments

Product

$57M52%

Bile Acid Products

$28M25%

Tiopronin Products

$26M24%